246 related articles for article (PubMed ID: 34579775)
1. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.
Mecinaj A; Gulati G; Heck SL; Holte E; Fagerland MW; Larsen AI; Blix ES; Geisler J; Wethal T; Omland T
Cardiooncology; 2021 Sep; 7(1):33. PubMed ID: 34579775
[TBL] [Abstract][Full Text] [Related]
2. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial.
Heck SL; Gulati G; Ree AH; Schulz-Menger J; Gravdehaug B; Røsjø H; Steine K; Bratland A; Hoffmann P; Geisler J; Omland T
Cardiology; 2012; 123(4):240-7. PubMed ID: 23207160
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial.
Tajstra M; Dyrbuś M; Rutkowski T; Składowski K; Sosnowska-Pasiarska B; Góźdź S; Radecka B; Staszewski M; Majsnerowska A; Myrda K; Nowowiejska-Wiewióra A; Skoczylas I; Rymkiewicz I; Niklewski T; Nowak J; Przybyłowski P; Gąsior M; Jarząb M
ESC Heart Fail; 2023 Oct; 10(5):3174-3183. PubMed ID: 37449716
[TBL] [Abstract][Full Text] [Related]
6. Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
Cannata F; Stefanini G; Carlo-Stella C; Chiarito M; Figliozzi S; Novelli L; Lisi C; Bombace S; Panico C; Cosco F; Corrado F; Masci G; Mazza R; Ricci F; Monti L; Ferrante G; Santoro A; Francone M; da Costa BR; Jüni P; Condorelli G
J Cardiovasc Med (Hagerstown); 2023 Jul; 24(7):469-474. PubMed ID: 37285278
[TBL] [Abstract][Full Text] [Related]
7. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Gulati G; Heck SL; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; von Knobelsdorff-Brenkenhoff F; Bratland Å; Storås TH; Hagve TA; Røsjø H; Steine K; Geisler J; Omland T
Eur Heart J; 2016 Jun; 37(21):1671-80. PubMed ID: 26903532
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
12. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
13. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
15. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
Kirkham AA; Paterson DI; Prado CM; Mackey JR; Courneya KS; Pituskin E; Thompson RB
BMC Cancer; 2018 Sep; 18(1):864. PubMed ID: 30176834
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
[TBL] [Abstract][Full Text] [Related]
18. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.
Gregorietti V; Fernandez TL; Costa D; Chahla EO; Daniele AJ
Cardiooncology; 2020 Nov; 6(1):24. PubMed ID: 33292750
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.
Livi L; Barletta G; Martella F; Saieva C; Desideri I; Bacci C; Del Bene MR; Airoldi M; Amoroso D; Coltelli L; Scotti V; Becherini C; Visani L; Salvestrini V; Mariotti M; Pedani F; Bernini M; Sanchez L; Orzalesi L; Nori J; Bianchi S; Olivotto I; Meattini I
JAMA Oncol; 2021 Oct; 7(10):1544-1549. PubMed ID: 34436523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]